[go: up one dir, main page]

DK3181128T3 - Farmaceutisk nilotinib-sammensætning - Google Patents

Farmaceutisk nilotinib-sammensætning Download PDF

Info

Publication number
DK3181128T3
DK3181128T3 DK17155689.7T DK17155689T DK3181128T3 DK 3181128 T3 DK3181128 T3 DK 3181128T3 DK 17155689 T DK17155689 T DK 17155689T DK 3181128 T3 DK3181128 T3 DK 3181128T3
Authority
DK
Denmark
Prior art keywords
nilotinib
pharmaceutical composition
pharmaceutical
composition
nilotinib pharmaceutical
Prior art date
Application number
DK17155689.7T
Other languages
English (en)
Inventor
Magnus Brisander
Gérald Jesson
Martin Malmsten
Helene Dérand
Mustafa Demirbuker
Original Assignee
Xspray Pharma Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xspray Pharma Ab Publ filed Critical Xspray Pharma Ab Publ
Application granted granted Critical
Publication of DK3181128T3 publication Critical patent/DK3181128T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Window Of Vehicle (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
DK17155689.7T 2012-01-13 2013-01-11 Farmaceutisk nilotinib-sammensætning DK3181128T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261586187P 2012-01-13 2012-01-13
SE1250015 2012-01-13
US201261713120P 2012-10-12 2012-10-12
SE1251160 2012-10-12
EP13736055.8A EP2802316A4 (en) 2012-01-13 2013-01-11 PHARMACEUTICAL COMPOSITION CONTAINING STABLE AMORPHOUS HYBRID NANOPARTICLES OF AT LEAST ONE INHIBITOR OF PROTEIN KINASE AND AT LEAST ONE STABILIZING AND MATRIXAL POLYMER COMPONENT

Publications (1)

Publication Number Publication Date
DK3181128T3 true DK3181128T3 (da) 2023-06-06

Family

ID=48781736

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17155689.7T DK3181128T3 (da) 2012-01-13 2013-01-11 Farmaceutisk nilotinib-sammensætning
DK17155686.3T DK3181122T3 (da) 2012-01-13 2013-01-11 Farmaceutisk dasatinib-sammensætning

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17155686.3T DK3181122T3 (da) 2012-01-13 2013-01-11 Farmaceutisk dasatinib-sammensætning

Country Status (15)

Country Link
US (23) US20140378454A1 (da)
EP (7) EP3181127B1 (da)
JP (13) JP6238310B2 (da)
CN (4) CN107115317A (da)
AU (8) AU2013208324B2 (da)
CA (2) CA2860932C (da)
DK (2) DK3181128T3 (da)
ES (2) ES2946735T3 (da)
FI (2) FI3181122T3 (da)
HR (2) HRP20230510T1 (da)
IL (4) IL293779B2 (da)
IN (1) IN2014DN06529A (da)
MX (4) MX347456B (da)
PL (3) PL3181128T3 (da)
WO (2) WO2013105895A1 (da)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2854751T3 (es) * 2012-01-13 2021-09-22 Xspray Microparticles Ab Un procedimiento para producir nanopartículas híbridas amorfas estables que comprende al menos un inhibidor de la proteína cinasa y al menos un componente polimérico estabilizante y formador de matriz
CN107115317A (zh) 2012-01-13 2017-09-01 X喷雾微粒公司 包含稳定的、无定形杂化纳米颗粒的药物组合物
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
CN104367557A (zh) * 2013-08-12 2015-02-25 浙江九洲药业股份有限公司 无定型药物活性成分与pvp组合物的制备方法
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
UA121967C2 (uk) 2014-03-14 2020-08-25 Пфайзер Інк. Терапевтичні наночастинки, які містять терапевтичний засіб, та способи їх отримання та застосування
WO2015145145A1 (en) * 2014-03-24 2015-10-01 Cipla Limited Pharmaceutical composition comprising lapatinib
WO2015145157A1 (en) * 2014-03-28 2015-10-01 Cipla Limited Pharmaceutical composition comprising pazopanib
EP3160449B1 (en) 2014-06-24 2023-12-13 The Trustees of Princeton University Process for encapsulating soluble biologics, therapeutics, and imaging agents
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
RU2017106795A (ru) 2014-08-07 2018-09-07 Фармасайкликс Элэлси Новые составы ингибитора тирозинкиназы брутона
US20170360791A1 (en) * 2014-12-04 2017-12-21 Astex Pharmaceuticals, Inc. Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs
WO2016097011A1 (en) * 2014-12-19 2016-06-23 Synthon B.V. Pharmaceutical composition comprising amorphous nilotinib
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
BR112017020216A2 (pt) * 2015-03-24 2018-05-22 Dow Global Technologies Llc ?composição aquosa?.
CZ2015250A3 (cs) * 2015-04-14 2016-10-26 Zentiva, K.S. Amorfní formy vemurafenibu
KR102643821B1 (ko) 2015-06-06 2024-03-07 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
EP3393647A4 (en) 2015-12-22 2019-08-21 The Trustees of Princeton University PROCESS FOR CAPACITING SOLUBLE BIOLOGICS, THERAPEUTICS AND CONTRASTANTS
WO2017108605A1 (en) 2015-12-22 2017-06-29 Synthon B.V. Pharmaceutical composition comprising amorphous dasatinib
ES2935158T3 (es) * 2016-03-17 2023-03-02 Sun Pharmaceutical Ind Ltd Composición farmacéutica de nilotinib
JP6739275B2 (ja) * 2016-08-02 2020-08-12 日本化薬株式会社 ゲフィチニブを有効成分とする医薬組成物
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
MA47798A (fr) * 2017-03-15 2020-01-22 Sun Pharma Advanced Res Co Ltd Nouvelle dispersion amorphe d'acide cyclopropanecarboxylique (5-{5-[ n'-(2-chloro-6-méthylbenzoyl) hydrazinocarbonyl] -2-méthyl-phényléthynyl}-pyridin-2-yl) amide
WO2018167802A1 (en) * 2017-03-15 2018-09-20 Sun Pharma Advanced Research Company Limited Novel amorphous dispersion of 4-methyl-3-quinolin-3-ylethynyl-benzoic acid n'-(2-chloro-6-methyl-benzoyl) hydrazide
BR112019019649A2 (pt) 2017-04-06 2020-04-14 Johnson Matthey Plc forma hidratada e cristalina de dimaleato de afatinibe, composição farmacêutica, e, métodos para tratamento de doença em um paciente e para produção da forma z.
WO2018203636A1 (ko) * 2017-05-02 2018-11-08 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
KR102082775B1 (ko) * 2017-05-02 2020-02-28 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 조성물
CN107157941B (zh) * 2017-05-16 2020-12-25 北京化工大学 一种达沙替尼纳米制剂及其制备方法
CN107011262B (zh) * 2017-06-01 2019-10-29 中国药科大学 一种基于超临界抗溶剂技术制备甲苯磺酸索拉非尼多晶型k微粒的方法
WO2019055539A1 (en) * 2017-09-12 2019-03-21 Prudhomme Robert K CELLULOSIC POLYMER NANOPARTICLES AND METHODS OF FORMING THE SAME
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
KR101922369B1 (ko) * 2018-01-12 2018-11-26 한국지질자원연구원 경구 생체이용률 개선을 위한 약물-층상형 실리케이트 복합체, 이를 포함하는 경구용 약학 조성물 및 상기 복합체의 제조 방법
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
WO2019209908A1 (en) 2018-04-25 2019-10-31 Johnson Matthey Public Limited Company Crystalline forms of dasatinib
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2019246479A1 (en) 2018-06-22 2019-12-26 Johnson Matthey Public Limited Company Form of ponatinib
WO2020018890A1 (en) 2018-07-19 2020-01-23 Prudhomme Robert K Triblock copolymer stabilizers for the formation of nanoparticles encapsulating soluble biologics, therapeutics, and imaging agents
US11731099B2 (en) 2018-07-20 2023-08-22 The Trustees Of Princeton University Method for controlling encapsulation efficiency and burst release of water soluble molecules from nanoparticles and microparticles produced by inverse flash nanoprecipitation
CN109833483B (zh) * 2018-09-17 2020-10-23 山东大学 基于小分子伴侣的索拉非尼纳米药物的制备
WO2020072870A1 (en) 2018-10-05 2020-04-09 Johnson Matthey Public Limited Company Co-crystal forms of baricitinib
CN109044977A (zh) * 2018-10-26 2018-12-21 武汉工程大学 一种乐伐替尼固体分散体及其制备方法和制剂
MX2021004965A (es) * 2018-11-06 2021-06-15 Beijing Innocare Pharma Tech Co Ltd Dispersion solida amorfa que comprende 6-(1-acriloilpiperidin-4-il )-2-(4-fenoxifenil)nicotinamida.
EP4509123A2 (en) * 2019-02-18 2025-02-19 Slayback Pharma LLC Pharmaceutical compositions of nilotinib
US10799459B1 (en) 2019-05-17 2020-10-13 Xspray Microparticles Ab Rapidly disintegrating solid oral dosage forms containing dasatinib
MX2022003347A (es) 2019-09-23 2022-04-11 Bionomics Ltd Formulaciones terapeuticas y usos de las mismas.
CN110801434A (zh) * 2019-10-31 2020-02-18 金华职业技术学院 一种冻干法制备甲苯磺酸拉帕替尼固体分散体的方法
WO2021150981A1 (en) 2020-01-24 2021-07-29 Nanocopoeia, Llc Amorphous solid dispersions of dasatinib and uses thereof
AU2021212258A1 (en) 2020-01-31 2022-09-29 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
EP3861989A1 (en) * 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
CN112294971B (zh) * 2020-02-20 2022-02-01 深圳市泰力生物医药有限公司 具有改进的溶解性的尼洛替尼组合物
CN111358952B (zh) * 2020-04-15 2022-03-15 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种抗肿瘤药物组合物及其制剂和应用
EP4142699A1 (en) 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN111467501B (zh) * 2020-05-22 2021-06-15 深圳市泰力生物医药有限公司 具有改良溶出性质的组合物
CN111973596B (zh) * 2020-06-15 2022-02-15 深圳市泰力生物医药有限公司 具有改良溶出性质的抗肺纤维化组合物
KR20230044423A (ko) * 2020-07-23 2023-04-04 크리티테크, 인크. 라파티닙 입자 및 이의 용도
WO2022034914A1 (ja) * 2020-08-13 2022-02-17 カルナバイオサイエンス株式会社 易溶性固形製剤およびその製法
JP2023543815A (ja) 2020-09-29 2023-10-18 シェンチェン ファーマシン シーオー．，エルティーディー． 医薬組成物
CA3194380A1 (en) 2020-10-02 2022-04-07 Michael MORGEN Acetic acid as processing aid in spray drying for basic drugs
US20230310393A1 (en) * 2020-12-07 2023-10-05 Tianjin Creatron Biotechnology Co., Ltd. Sorafenib pharmaceutical composition with high bioavailability and use thereof
US11529351B2 (en) 2021-01-21 2022-12-20 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
US11980619B2 (en) 2021-07-28 2024-05-14 Nanocopoeia, Llc Pharmaceutical compositions and crushable tablets including amorphous solid dispersions of dasatinib and uses
JP2024528736A (ja) * 2021-07-30 2024-07-30 上海雲晟研新生物科技有限公司 パゾパニブ経口医薬組成物、その製造方法及び応用
KR102686558B1 (ko) * 2022-01-25 2024-07-22 (주)피알지에스앤텍 프로게리닌을 포함하는 과립제 및 이를 이용한 샤셋제
WO2023155182A1 (zh) * 2022-02-21 2023-08-24 北京睿创康泰医药研究院有限公司 一种低服用剂量高药物暴露量的索拉非尼或多纳非尼口服制剂及其应用
TW202428307A (zh) * 2022-10-12 2024-07-16 日商中外製藥股份有限公司 包含胜肽、界面活性劑及聚合物的組成物
KR20240115650A (ko) * 2023-01-19 2024-07-26 주식회사 스카이테라퓨틱스 티로신 키나아제 억제제의 무정형 나노 분자회합체와 이를 포함하는 조성물 및 그의 제조방법
CN116688139B (zh) * 2023-06-25 2024-03-29 深圳市新阳唯康科技有限公司 一种克唑替尼药物组合物及其制备方法和应用
CN117100715B (zh) * 2023-09-05 2024-10-15 深圳市泰力生物医药有限公司 一种含无定型尼洛替尼的胶囊及其制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6406781B1 (en) * 1998-06-23 2002-06-18 3M Innovative Properties Company Stretch release adhesive article with stabilizer
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
GB9925934D0 (en) 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
US20040256749A1 (en) 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
SE0303476D0 (sv) 2003-12-22 2003-12-22 Censdelivery Ab Device, method and use for the formation of small particles
US7625911B2 (en) * 2005-01-12 2009-12-01 Mai De Ltd. Amorphous form of erlotinib hydrochloride and its solid amorphous dispersion
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
WO2007133750A2 (en) * 2006-05-12 2007-11-22 The Board Of Trustees Of The Leland Stanford Junior University Encapsulated nanoparticles for drug delivery
CA2654909A1 (en) * 2006-06-13 2007-12-21 Elan Pharma International Ltd. Nanoparticulate kinase inhibitor formulations
TW200820991A (en) * 2006-07-10 2008-05-16 Elan Pharma Int Ltd Nanoparticulate sorafenib formulations
AU2007316558A1 (en) 2006-11-09 2008-05-15 Abbott Gmbh & Co. Kg Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
EP1920767A1 (en) 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP3252047B1 (en) 2007-04-05 2022-05-11 Pfizer Products Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
US7823700B2 (en) * 2007-07-20 2010-11-02 International Business Machines Corporation User identification enabled elevator control method and system
CA2706684C (en) * 2007-12-07 2016-01-12 Xspray Microparticles Ab Method and arrangement for the production of particles
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
US20090203709A1 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor
EP2105130A1 (de) 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
GB0909154D0 (en) 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
US9050317B2 (en) * 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
CZ20098A3 (cs) 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz
US8603521B2 (en) * 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
KR100924236B1 (ko) * 2009-06-23 2009-10-29 충남대학교산학협력단 균일한 입도분포를 가지는 초미세입자의 신규한 제조방법 및 장치
WO2011159218A1 (en) 2010-06-14 2011-12-22 Xspray Microparticles Ab Apparatus and method for the production of particles
CN103179955B (zh) * 2010-09-14 2016-08-03 纳诺洛吉卡股份公司 用于不良水溶性的药物和化妆活性成分的过饱和释放赋形剂
CN107115317A (zh) * 2012-01-13 2017-09-01 X喷雾微粒公司 包含稳定的、无定形杂化纳米颗粒的药物组合物
JP2017141910A (ja) * 2016-02-10 2017-08-17 武蔵精密工業株式会社 伝動装置
JP6688624B2 (ja) * 2016-02-11 2020-04-28 学校法人 名城大学 ガスタンク及びこのガスタンクを複数備えたガスの貯蔵供給設備
JP6767610B2 (ja) * 2016-02-12 2020-10-14 パナソニックＩｐマネジメント株式会社 断熱体とその製造方法
WO2022177983A1 (en) * 2021-02-19 2022-08-25 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib

Also Published As

Publication number Publication date
FI3181128T3 (fi) 2023-06-02
AU2018200928A1 (en) 2018-03-01
IL233582B (en) 2021-09-30
JP2021073228A (ja) 2021-05-13
CA2860932A1 (en) 2013-07-18
EP3181122B1 (en) 2023-03-08
PL3181122T3 (pl) 2023-07-31
US20210093616A1 (en) 2021-04-01
AU2019275513B2 (en) 2022-03-10
CA2860973C (en) 2021-10-26
AU2021269328B2 (en) 2024-07-25
JP2018012713A (ja) 2018-01-25
JP7006995B2 (ja) 2022-01-24
US20170143683A1 (en) 2017-05-25
EP3766486A1 (en) 2021-01-20
US20160250153A1 (en) 2016-09-01
JP6628834B2 (ja) 2020-01-15
MX2022003458A (es) 2022-06-02
US20240398769A1 (en) 2024-12-05
MX2023008180A (es) 2023-08-03
MX347456B (es) 2017-04-27
EP2802316A4 (en) 2015-11-18
JP2019070000A (ja) 2019-05-09
EP2802316A1 (en) 2014-11-19
US10314830B2 (en) 2019-06-11
US20190275018A1 (en) 2019-09-12
JP6463416B2 (ja) 2019-02-06
JP6463418B2 (ja) 2019-02-06
AU2018200933A1 (en) 2018-03-01
JP7391507B2 (ja) 2023-12-05
JP6238310B2 (ja) 2017-11-29
MX2014008457A (es) 2015-02-12
US20220168285A1 (en) 2022-06-02
US9833442B2 (en) 2017-12-05
JP2018012714A (ja) 2018-01-25
EP2802314A1 (en) 2014-11-19
AU2018200931B2 (en) 2019-07-18
US20240189290A1 (en) 2024-06-13
DK3181122T3 (da) 2023-06-06
AU2018200928B2 (en) 2019-07-18
WO2013105895A1 (en) 2013-07-18
US11963951B2 (en) 2024-04-23
IN2014DN06529A (da) 2015-06-12
EP2802314B1 (en) 2020-11-25
US20250090511A1 (en) 2025-03-20
JP6238311B2 (ja) 2017-11-29
EP3181128B1 (en) 2023-03-08
JP2015503612A (ja) 2015-02-02
EP3181122A1 (en) 2017-06-21
US20190076413A1 (en) 2019-03-14
FI3181122T3 (fi) 2023-05-31
CN107115318A (zh) 2017-09-01
EP2802314A4 (en) 2015-08-12
IL293775A (en) 2022-08-01
EP3181127B1 (en) 2023-03-08
CN104159577A (zh) 2014-11-19
JP6463417B2 (ja) 2019-02-06
US10561645B2 (en) 2020-02-18
US9827230B2 (en) 2017-11-28
US20170143715A1 (en) 2017-05-25
US20190255029A1 (en) 2019-08-22
PL3181128T3 (pl) 2023-07-31
HRP20230510T1 (hr) 2023-10-27
US11376243B2 (en) 2022-07-05
JP6463419B2 (ja) 2019-02-06
US9456992B2 (en) 2016-10-04
US20190060294A1 (en) 2019-02-28
JP2018035147A (ja) 2018-03-08
US12076314B2 (en) 2024-09-03
US10143683B2 (en) 2018-12-04
AU2013208323B2 (en) 2017-07-06
US10314829B2 (en) 2019-06-11
CN104159577B (zh) 2017-03-15
US10561643B2 (en) 2020-02-18
EP4218740A1 (en) 2023-08-02
IL233583B (en) 2020-10-29
JP2018008973A (ja) 2018-01-18
JP2015503613A (ja) 2015-02-02
EP3181127A1 (en) 2017-06-21
US11426391B2 (en) 2022-08-30
AU2013208324B2 (en) 2017-11-23
US20220117947A1 (en) 2022-04-21
US10555937B2 (en) 2020-02-11
CN104159574A (zh) 2014-11-19
JP2017222694A (ja) 2017-12-21
CA2860973A1 (en) 2013-07-18
CN107115317A (zh) 2017-09-01
AU2018200931A1 (en) 2018-03-01
CA2860932C (en) 2021-02-16
EP3181128A1 (en) 2017-06-21
IL293779A (en) 2022-08-01
US20240374577A1 (en) 2024-11-14
US20200253941A1 (en) 2020-08-13
IL293779B2 (en) 2023-09-01
US20220160687A1 (en) 2022-05-26
WO2013105894A1 (en) 2013-07-18
JP6351810B2 (ja) 2018-07-04
IL293775B2 (en) 2023-05-01
IL293775B1 (en) 2023-01-01
AU2018200933B2 (en) 2020-01-02
US10772877B2 (en) 2020-09-15
MX2020000984A (es) 2020-07-13
US11241419B2 (en) 2022-02-08
ES2946549T3 (es) 2023-07-20
AU2019275513A1 (en) 2019-12-19
IL233583A0 (en) 2014-08-31
US20220296575A1 (en) 2022-09-22
AU2021269331B2 (en) 2024-07-25
PL2802314T3 (pl) 2021-06-14
US10561644B2 (en) 2020-02-18
US20160361313A1 (en) 2016-12-15
US20190275019A1 (en) 2019-09-12
US20190282553A1 (en) 2019-09-19
AU2021269331A1 (en) 2021-12-09
US12144804B1 (en) 2024-11-19
US20140356443A1 (en) 2014-12-04
US11517562B2 (en) 2022-12-06
US20140378454A1 (en) 2014-12-25
HRP20230529T1 (hr) 2023-09-15
JP6351811B2 (ja) 2018-07-04
AU2013208324A1 (en) 2014-07-24
AU2013208323A1 (en) 2014-07-24
JP2018172393A (ja) 2018-11-08
IL233582A0 (en) 2014-08-31
JP2017222695A (ja) 2017-12-21
US9833443B2 (en) 2017-12-05
AU2021269328A1 (en) 2021-12-09
JP2023123773A (ja) 2023-09-05
JP2017222693A (ja) 2017-12-21
ES2946735T3 (es) 2023-07-25
US20180042906A1 (en) 2018-02-15
JP6351809B2 (ja) 2018-07-04
IL293779B1 (en) 2023-05-01

Similar Documents

Publication Publication Date Title
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
SMT201700008B (it) Composizione farmaceutica
DK2694038T3 (da) Farmaceutisk sammensætning
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
BR112014003052A2 (pt) composições farmacêuticas
DK2812000T3 (da) Flerlaget nikotinholdig farmaceutisk sammensætning
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK3246018T3 (da) Farmaceutisk sammensætning
CO6930367A2 (es) Composiciones farmaceúticas
ZA201501930B (en) Pharmaceutical composition
HK1209638A1 (en) Pharmaceutical compositions
ZA201501928B (en) Pharmaceutical antiretroviral composition
BR112013014644A2 (pt) composição farmacêutica e complexo
EE201300005A (et) Ravimkoostis
DK2897594T3 (da) Farmaceutisk sammensætning
HUE040370T2 (hu) Gyógyszerkészítmények
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
DK2815752T3 (da) Oral farmaceutisk sammensætning
CL2014003283A1 (es) Formulación farmacéutica.
BR112015003116A2 (pt) preparação farmacêutica sólida contendo levotiroxina
EP2769718A4 (en) MEDICAL COMPOSITION
EP2883547A4 (en) MEDICINE
BR112014015885A2 (pt) preparação farmacêutica
BR112015002646A2 (pt) composto e composição farmacêutica
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina